CA1052697A - Composition for treating mastitis in animals - Google Patents
Composition for treating mastitis in animalsInfo
- Publication number
- CA1052697A CA1052697A CA221,421A CA221421A CA1052697A CA 1052697 A CA1052697 A CA 1052697A CA 221421 A CA221421 A CA 221421A CA 1052697 A CA1052697 A CA 1052697A
- Authority
- CA
- Canada
- Prior art keywords
- fatty acid
- composition
- oil
- group
- mastitis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0041—Mammary glands, e.g. breasts, udder; Intramammary administration
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
ABSTRACT OF THE DISCLOSURE
Compositions and methods for treating mastitis in milk animals which comprises administering by intra-mammary infusion an effective amount of an anti-mastitis medicament dispersed in a vehicle comprising an oil, a fatty acid ester and, optionally, a fatty acid salt.
Compositions and methods for treating mastitis in milk animals which comprises administering by intra-mammary infusion an effective amount of an anti-mastitis medicament dispersed in a vehicle comprising an oil, a fatty acid ester and, optionally, a fatty acid salt.
Description
3:?40 ~osZ697 BACKGROUND OF THE INVENTION -Mastitis is an inflammatory condition of the mammary gland. It may affect any species, but bovine mastttis is of the greatest economic importance.
Bovine mastitis is usually associated with one or more microorganisms such às StrePtococcus aaalactiae, Streptococcus dysqalactTae, Staphlococcus aureus, Aero-bacter aeroqenes, Escherichia coli, Pseudomonas aeruqi-nosa, Salmonella enteritidis, C!ostridium Perfinqerls, and CorYnebacterium Pvoqenes which invade the udder through the teat canal and produce inflammation of the miIk-producing tissue causing the formation of scar tis- -sue which, once formed, may cause a permanent reduction in the cow's milk production, An infection can also alter the composition, quantity, appearance and quality ; of the milk, The etiology of mastTtis makes control of the problem dependent upon the crltical diagnosis of the spe-~ ciftc microbial agent involved, the correction of faulty `~ 20 managerial practlces and the Judicious use of in~ra-mammary therapy.
BRIEF SUMMARY OF THE INVENTION
~; This Invention relates to new mastitis composi-tions and to methods of treating mastitis in milk animals by intramammary infusion of an anti-mastitis ;~.
medicament dispersed in a special vehicle providing a short anti-mastitis medicament milk-out time.
The vehicle of the present invention comprises an oil and from 0.5 to 5.0~ by weight of a fatty acid ester of a member selected from the group consisting of Z ~
:' /~S~ ~ 9 ~
~ "~in, propylcne glyc~l J monO- and dihydric alcohol~ of from ,~
one to twelve carbon atoms, inclusive, and poly~thylene glycols having a molecular wei~ht of between about 200 and about 6000, said fatty acid being selected from a group consisting of long chain saturated and unsaturated monocarboxylic acids having from twelve to t~enty carbon atoms, inclusive. In addition to a fatty acid ester as described above, the vehicle of the present invention may optionally include from 0.02~ to 0.15~ by wei~ht of a fatty acid salt of a member selected from the group consisting of sodium, potassium and lithium, said fatty acid being selected from a group consisting of long chain saturated and unsaturated monocarboxylic acids having from twelve to twenty carbon atoms, inclusive.
DETAILED DESCRIPTION
The present invention relates to compositions and methods of treating mastitis in animals, particularly milk animals, by intramammary infusion. Milk animal is any animal which has mammary glands and is capable of milk production.
Although bovine mastitis is of the greatest economic importance and for convenience references herein will be directed ~20 essentially to such situations, it will be understood that the compositions and methods of the present invention are applicable to other milk animals as well.
The compositions and methods of the present invention are particularly advantageous for the treatment of mastitis because of a surprisingly short anti-mastitis medicament milk-out time, i.e., the ~ .
. , :~' . ' :
` B`~
... . . .
105'~697 3240 amount of timc requir~d for an anti-mastitis medicament to clear the udder after the last intramammal-y infusion.
This property of a short anti-mastitis medicament mil~-out time is of importance since milk contaminated with an anti-mastitis medicament cannot be used for human consumption or marketed for cheese production. -The nature of the vehicle, on anti-mastitis medicament milk-out times, has long been considered im-portant in formulating mastitis infusion compositions.
Heretofore, anti-mastitis medicaments for intra-mammary infusion have commonly been dispersed in an oil medlum such as mineral oil or a vegetable oil containing a trivalent metallic stearate such as aluminurn mono-stearate, e.g" a peanut oil medium containing 3~ of alum7num monostearate. A dTsadvantage with intramammary infusion compositions containing a trivalent metallic stearate, as described above, is that the anti-mastitis medicament milk-ollt time for such compositions is quite long.
It i5 therefore a principal object of this in-vention to provide compositions and methods for treating animal masti~is by intramammary infusions affording short anti-mastitis medicament milk-out times.
The term "anti-mastitis medicament", as used in the specification and claims, refers to any antimicrobial effective to treat mastitis. Illustrative of the anti-mastitis medicaments which can be utilized in the compo-sitions of the present invention include penicillin, neomycin, novobiocin~ lincomycin, dihydrostreptoll1ycin, streptomycin, erythromycir-, polymyxin, tetracycline, .. ; .
~o5~69~
oxytetracycllne, chlortetracycline, clindamycin, nitro-furazonq, cephalosporins, analogs andderlvatives thereof, and their pharmaceutically acceptable salts. The amount of anti-rnastitis medicament employed will, of course, vary depending upon the severity of the mastitis but, in general~ those amoun-ts which have heretofore bee used for the treatment of rnastitis are suitable.
In accordance with a sp~cific feature of 1:his Invention, the oil ot the vehicle may be any vegetabl~
oil which is suitable for carrying an anti-mastitis medlcament and which has been foun~i fully acceptable for intramammary Infusion. Vegetable oils may be generally classlfied as non-drying, semi~drying and drying oils.
Drying vegetable olls include linseed oil and safflower `~
oil. The dry7ng properties of this group of oils is caused by the presence of unsaturated fatty acids in the oll, The ~legree of unsatlIrated fatty aclds pr~sellt can be expressed by the iodine value of the oil. Arranged according to their lodlne value, t:he afoIemelll:ioned drying vegetable oils are as follows:
I.inseed oll not less ~har- 170 Safflower oll 140 - 150 ; The class of semi-drylng vegetable oils includes the followlng~ arranged accordlng to their iodine value.
Soybean oil 127 - 138 Cottonseed oil 105 - 114 Sesame oil 103 - 122 Corn oll 109 - 133 The class of non-drying vegetable oils includes the following, arranged acc~rding to their io~ine value:
. . .
Oli oil 79 - 90 Peanut oil ~ o 5 ~6 9~ 84 - 102 ~ s stated, vegetable oils are suitable for the vehicle, examples being peanut oil, sesame oil, corn oil, cotton-seed o:il, soybean oil, olive oil, and like vegetable oils or mixtures thereof. In a broader aspect, it is conceived that other oils may be employed, in part or in whole, for example, mineral oil. However, in such compositions, the milk-out specifications may require that the milk be completely clear -of such oil in order to be available for human consumption.
The term "mineral oil" as used in the specification and claims refers to mixtures of liquid hydrocarbons known in medicine as liquid paraffin and light liquid paraffin or petroleum, preferably those of the United States or British Pharmacopeias.
An oil, i.e., a vegetable oil or a mineral oil, is transformed to a gel before being incorporated into the com-positions of the present invention. This gelling is effected by treatment of the oil with a atty acid ester of a member selected . from the group consisting of glycerin, propylene glycol, mono-. , .
and dihydric alcohols of from one to twelve carbon atoms, inclusive,and polyethylene glycols having a molecular weight of between about 200 and about 6000, said fatty acid being selected from a group consisting of long chain saturàted and unsaturated mono-carboxylic acids having from twelve to twenty carbon atoms, inclusive. A preferred fatty acid ester of the present invention is glycerol monos~earate.
,~
.
., .` ~ .
~ ~ .
.. . . .. . . . . ... . . .. . ..
~ 105~'~697 The amount of glycerol monostearate or other fatty acid ester which can be used in accordance with this invention is generally within the range of between about 0.5 and 5.0% by weight, and preferably from 1.0 to 4.0% by weight. A gel formed by gelling peanut oil wi~h
Bovine mastitis is usually associated with one or more microorganisms such às StrePtococcus aaalactiae, Streptococcus dysqalactTae, Staphlococcus aureus, Aero-bacter aeroqenes, Escherichia coli, Pseudomonas aeruqi-nosa, Salmonella enteritidis, C!ostridium Perfinqerls, and CorYnebacterium Pvoqenes which invade the udder through the teat canal and produce inflammation of the miIk-producing tissue causing the formation of scar tis- -sue which, once formed, may cause a permanent reduction in the cow's milk production, An infection can also alter the composition, quantity, appearance and quality ; of the milk, The etiology of mastTtis makes control of the problem dependent upon the crltical diagnosis of the spe-~ ciftc microbial agent involved, the correction of faulty `~ 20 managerial practlces and the Judicious use of in~ra-mammary therapy.
BRIEF SUMMARY OF THE INVENTION
~; This Invention relates to new mastitis composi-tions and to methods of treating mastitis in milk animals by intramammary infusion of an anti-mastitis ;~.
medicament dispersed in a special vehicle providing a short anti-mastitis medicament milk-out time.
The vehicle of the present invention comprises an oil and from 0.5 to 5.0~ by weight of a fatty acid ester of a member selected from the group consisting of Z ~
:' /~S~ ~ 9 ~
~ "~in, propylcne glyc~l J monO- and dihydric alcohol~ of from ,~
one to twelve carbon atoms, inclusive, and poly~thylene glycols having a molecular wei~ht of between about 200 and about 6000, said fatty acid being selected from a group consisting of long chain saturated and unsaturated monocarboxylic acids having from twelve to t~enty carbon atoms, inclusive. In addition to a fatty acid ester as described above, the vehicle of the present invention may optionally include from 0.02~ to 0.15~ by wei~ht of a fatty acid salt of a member selected from the group consisting of sodium, potassium and lithium, said fatty acid being selected from a group consisting of long chain saturated and unsaturated monocarboxylic acids having from twelve to twenty carbon atoms, inclusive.
DETAILED DESCRIPTION
The present invention relates to compositions and methods of treating mastitis in animals, particularly milk animals, by intramammary infusion. Milk animal is any animal which has mammary glands and is capable of milk production.
Although bovine mastitis is of the greatest economic importance and for convenience references herein will be directed ~20 essentially to such situations, it will be understood that the compositions and methods of the present invention are applicable to other milk animals as well.
The compositions and methods of the present invention are particularly advantageous for the treatment of mastitis because of a surprisingly short anti-mastitis medicament milk-out time, i.e., the ~ .
. , :~' . ' :
` B`~
... . . .
105'~697 3240 amount of timc requir~d for an anti-mastitis medicament to clear the udder after the last intramammal-y infusion.
This property of a short anti-mastitis medicament mil~-out time is of importance since milk contaminated with an anti-mastitis medicament cannot be used for human consumption or marketed for cheese production. -The nature of the vehicle, on anti-mastitis medicament milk-out times, has long been considered im-portant in formulating mastitis infusion compositions.
Heretofore, anti-mastitis medicaments for intra-mammary infusion have commonly been dispersed in an oil medlum such as mineral oil or a vegetable oil containing a trivalent metallic stearate such as aluminurn mono-stearate, e.g" a peanut oil medium containing 3~ of alum7num monostearate. A dTsadvantage with intramammary infusion compositions containing a trivalent metallic stearate, as described above, is that the anti-mastitis medicament milk-ollt time for such compositions is quite long.
It i5 therefore a principal object of this in-vention to provide compositions and methods for treating animal masti~is by intramammary infusions affording short anti-mastitis medicament milk-out times.
The term "anti-mastitis medicament", as used in the specification and claims, refers to any antimicrobial effective to treat mastitis. Illustrative of the anti-mastitis medicaments which can be utilized in the compo-sitions of the present invention include penicillin, neomycin, novobiocin~ lincomycin, dihydrostreptoll1ycin, streptomycin, erythromycir-, polymyxin, tetracycline, .. ; .
~o5~69~
oxytetracycllne, chlortetracycline, clindamycin, nitro-furazonq, cephalosporins, analogs andderlvatives thereof, and their pharmaceutically acceptable salts. The amount of anti-rnastitis medicament employed will, of course, vary depending upon the severity of the mastitis but, in general~ those amoun-ts which have heretofore bee used for the treatment of rnastitis are suitable.
In accordance with a sp~cific feature of 1:his Invention, the oil ot the vehicle may be any vegetabl~
oil which is suitable for carrying an anti-mastitis medlcament and which has been foun~i fully acceptable for intramammary Infusion. Vegetable oils may be generally classlfied as non-drying, semi~drying and drying oils.
Drying vegetable olls include linseed oil and safflower `~
oil. The dry7ng properties of this group of oils is caused by the presence of unsaturated fatty acids in the oll, The ~legree of unsatlIrated fatty aclds pr~sellt can be expressed by the iodine value of the oil. Arranged according to their lodlne value, t:he afoIemelll:ioned drying vegetable oils are as follows:
I.inseed oll not less ~har- 170 Safflower oll 140 - 150 ; The class of semi-drylng vegetable oils includes the followlng~ arranged accordlng to their iodine value.
Soybean oil 127 - 138 Cottonseed oil 105 - 114 Sesame oil 103 - 122 Corn oll 109 - 133 The class of non-drying vegetable oils includes the following, arranged acc~rding to their io~ine value:
. . .
Oli oil 79 - 90 Peanut oil ~ o 5 ~6 9~ 84 - 102 ~ s stated, vegetable oils are suitable for the vehicle, examples being peanut oil, sesame oil, corn oil, cotton-seed o:il, soybean oil, olive oil, and like vegetable oils or mixtures thereof. In a broader aspect, it is conceived that other oils may be employed, in part or in whole, for example, mineral oil. However, in such compositions, the milk-out specifications may require that the milk be completely clear -of such oil in order to be available for human consumption.
The term "mineral oil" as used in the specification and claims refers to mixtures of liquid hydrocarbons known in medicine as liquid paraffin and light liquid paraffin or petroleum, preferably those of the United States or British Pharmacopeias.
An oil, i.e., a vegetable oil or a mineral oil, is transformed to a gel before being incorporated into the com-positions of the present invention. This gelling is effected by treatment of the oil with a atty acid ester of a member selected . from the group consisting of glycerin, propylene glycol, mono-. , .
and dihydric alcohols of from one to twelve carbon atoms, inclusive,and polyethylene glycols having a molecular weight of between about 200 and about 6000, said fatty acid being selected from a group consisting of long chain saturàted and unsaturated mono-carboxylic acids having from twelve to twenty carbon atoms, inclusive. A preferred fatty acid ester of the present invention is glycerol monos~earate.
,~
.
., .` ~ .
~ ~ .
.. . . .. . . . . ... . . .. . ..
~ 105~'~697 The amount of glycerol monostearate or other fatty acid ester which can be used in accordance with this invention is generally within the range of between about 0.5 and 5.0% by weight, and preferably from 1.0 to 4.0% by weight. A gel formed by gelling peanut oil wi~h
2.0% by weight of glycerol monostearate is a preferred vehicle for the preparation of compositions of this invention.
Optionally, the vehicle of the present invention . may also include a fatty acid salt of a member selected from the group consisting of sodium, potassium and lithium, said ' fatty acid being selected from a group consisting of long --chain saturated and unsaturated monocarboxylic acids having '' from twelve to twenty carbon atoms, inclusive. A preferred fatty acid salt of the present invention is potassium stearate.
'- The amount of potassium stearate or other fatty acid salt which can be used in accordance with this invention is generally within the range of between about 0.02% and 0.15%
by weight. ~ gel formed by gelling peanut oil with 2.0% by weight of glycerol'monostearate and 0.12% by weight'of 20 ' potassium stearate produces an eminently satisfactory vehicle for the preparation of the compositions of this invention.
To gel a mineral oll or a vegetable oil, the oil ~- is heated to a suitable temperature which may vary somewhat ' with different oils but which will generally `be below 100C.
' ~ Peanut oil, for example,'can be readily gelled by heating it to 60-90C. and adding 2.0% by weight of glycerol monostearate, '' and then cooling to .'''.~ . .
~ . .
~' '' . ' , _ 7 _ .
Optionally, the vehicle of the present invention . may also include a fatty acid salt of a member selected from the group consisting of sodium, potassium and lithium, said ' fatty acid being selected from a group consisting of long --chain saturated and unsaturated monocarboxylic acids having '' from twelve to twenty carbon atoms, inclusive. A preferred fatty acid salt of the present invention is potassium stearate.
'- The amount of potassium stearate or other fatty acid salt which can be used in accordance with this invention is generally within the range of between about 0.02% and 0.15%
by weight. ~ gel formed by gelling peanut oil with 2.0% by weight of glycerol'monostearate and 0.12% by weight'of 20 ' potassium stearate produces an eminently satisfactory vehicle for the preparation of the compositions of this invention.
To gel a mineral oll or a vegetable oil, the oil ~- is heated to a suitable temperature which may vary somewhat ' with different oils but which will generally `be below 100C.
' ~ Peanut oil, for example,'can be readily gelled by heating it to 60-90C. and adding 2.0% by weight of glycerol monostearate, '' and then cooling to .'''.~ . .
~ . .
~' '' . ' , _ 7 _ .
3~4 1 0 5'~ ~ 9 7 25 C. wl~h stlrrlng. Thers Is no great danger in over-heatlng, pr~vlded d~composltion of the oll Is no~ engen-dered. ~ea~e~ olls are gelled wlth a fatty acid esteru The method of treatlng mas~itis In accordance 'j wlth the present Inventlon involves admlnlstering to ~he affect~d mammary gland iy Intramammary Infusion a compo-sltlo-l as hereln descrlbed.
The followlng sxamples are Illustratlve of the best mod~ contemplated by the Inventor for carrylng o~t hls Inventlon and are not to be construed as llmitlng.
EX~nD1~ 1 One hundred grams of e composltlon for the treat-. ment of mastltls Is prepared ~rom the fol,lowlng types and amounts ~f Ingredlonts~ '' Procalne Penlclllln G500,000 Unlts Sodlum Novoblocln 1.00 gram Glyc~rol m~nostearate1,00 gram Peanut oll, q.s. 100 grams ~eat the peanut oll to 60-goc. and add the glyc~
~rol monost~ar~t~, cool to 25~C. wlth s~lrrlng. Ad(l the sodlum novoblocln and procalne penlc~ltln G wlth stlr-rlng and pass tho product through a collold mlll. Flll the mllled product Into dlsposable mastltls syrlnges In 10 gram doses.
The ~oregolng oomposlt!on Is useful for the treatmen~ of bovlne mastltls by Intramammary,lnfuslon.
One hundred grams of a composltion for the treat-ment of mas~ltls Is prepared from the followlng types and amoun~s of Ingredtents:
' ~ 8~
-` 3240 IoS~69~ ~
Procalne Peniclllln G1,500,000 Units Sodium Novobiocln 1.500 gram Glyceryl monostearate1,425 gram Potasslum stearate 0.075 gram Peanut oll, q.s. 100 grams Heat the peanut oil to 60-90C. and add the glyceryl monostearate and potasslum stearate, cool to 25 C. wlth stlrrlng. Add the sodlum novobtoc7n and procalne penlcillIn G with stirring and pass the product through a collold mlll. Fill the m711ed product into disposable mastit1s syringes in 10 gram doses.
The foregoing composltion is useful for the treatment of bovtne mastitls by intramammary infusion.
Exam~le ~
One hundred grams of a composltion for ths treat-rnent of mastltis Is prepared from the following types and-amounts of ingredlents: -Lincomycln hydrochloride 2.0 grams Glycerol monostearate 2.0 grarns Peanut oll, q.s~ 100 grams - Heat the peanut oil to 60-goc. and add the glycer~l monostearate, cool to 25 C. with stirring. Add .; ~
the lincomycin hydrochloride ~ith stirring and pass the ? product through a colloid mill. Fill the milled product ~., . I .
2S into disposable mastitls syringes in 10 gram doses.
~-~ The foregoing compositlon Ts useful for the treatment of bov1ne mastltis by intramammary infusion.
~, Example 4 One hundred grams of a composition for the treat-30 ment of mastitis is prepared from the following types . .
~. _g_ . ' . .
~05'~697 ~ ,an(~ am~unts of ingredients:
; Procaine Penicillin G500,000 Units Sodlum Novobiocin 1.00 gram Glyceryl monostearate1.00 gram Mineral oil, q.s. 100 grams Heat the mineral oil to 60-90C. and add the glyceryl monostearate, cool to 25C. with stirring. Add the procaine penicillin G and sodium novobiocin with s-tirring and pass the product through a colloid mill.
Fill the milled product into disposable mastitis sy-ringes in 10 gram doses.
The foregoing composition is useful for the treatment of bovine rnastltis by intramalnmary infusion.
.. . .
~' .
~''' .
. ~
; .
The followlng sxamples are Illustratlve of the best mod~ contemplated by the Inventor for carrylng o~t hls Inventlon and are not to be construed as llmitlng.
EX~nD1~ 1 One hundred grams of e composltlon for the treat-. ment of mastltls Is prepared ~rom the fol,lowlng types and amounts ~f Ingredlonts~ '' Procalne Penlclllln G500,000 Unlts Sodlum Novoblocln 1.00 gram Glyc~rol m~nostearate1,00 gram Peanut oll, q.s. 100 grams ~eat the peanut oll to 60-goc. and add the glyc~
~rol monost~ar~t~, cool to 25~C. wlth s~lrrlng. Ad(l the sodlum novoblocln and procalne penlc~ltln G wlth stlr-rlng and pass tho product through a collold mlll. Flll the mllled product Into dlsposable mastltls syrlnges In 10 gram doses.
The ~oregolng oomposlt!on Is useful for the treatmen~ of bovlne mastltls by Intramammary,lnfuslon.
One hundred grams of a composltion for the treat-ment of mas~ltls Is prepared from the followlng types and amoun~s of Ingredtents:
' ~ 8~
-` 3240 IoS~69~ ~
Procalne Peniclllln G1,500,000 Units Sodium Novobiocln 1.500 gram Glyceryl monostearate1,425 gram Potasslum stearate 0.075 gram Peanut oll, q.s. 100 grams Heat the peanut oil to 60-90C. and add the glyceryl monostearate and potasslum stearate, cool to 25 C. wlth stlrrlng. Add the sodlum novobtoc7n and procalne penlcillIn G with stirring and pass the product through a collold mlll. Fill the m711ed product into disposable mastit1s syringes in 10 gram doses.
The foregoing composltion is useful for the treatment of bovtne mastitls by intramammary infusion.
Exam~le ~
One hundred grams of a composltion for ths treat-rnent of mastltis Is prepared from the following types and-amounts of ingredlents: -Lincomycln hydrochloride 2.0 grams Glycerol monostearate 2.0 grarns Peanut oll, q.s~ 100 grams - Heat the peanut oil to 60-goc. and add the glycer~l monostearate, cool to 25 C. with stirring. Add .; ~
the lincomycin hydrochloride ~ith stirring and pass the ? product through a colloid mill. Fill the milled product ~., . I .
2S into disposable mastitls syringes in 10 gram doses.
~-~ The foregoing compositlon Ts useful for the treatment of bov1ne mastltis by intramammary infusion.
~, Example 4 One hundred grams of a composition for the treat-30 ment of mastitis is prepared from the following types . .
~. _g_ . ' . .
~05'~697 ~ ,an(~ am~unts of ingredients:
; Procaine Penicillin G500,000 Units Sodlum Novobiocin 1.00 gram Glyceryl monostearate1.00 gram Mineral oil, q.s. 100 grams Heat the mineral oil to 60-90C. and add the glyceryl monostearate, cool to 25C. with stirring. Add the procaine penicillin G and sodium novobiocin with s-tirring and pass the product through a colloid mill.
Fill the milled product into disposable mastitis sy-ringes in 10 gram doses.
The foregoing composition is useful for the treatment of bovine rnastltis by intramalnmary infusion.
.. . .
~' .
~''' .
. ~
; .
Claims (9)
PROPERTY OR PRIVILEGE IS CLAIMED ARE DEFINED AS FOLLOWS:
1. A composition for treating mastitis in milk animals by intramammary infusion which comprises an effective amount of an anti-mastitis medicament dispersed in a gelled vehicle com-prising a vegetable oil selected from the group consisting of non-drying, semi-drying, and drying oils and blends of non-drying oils and an oil selected from the group consisting of semi-drying and drying oils; and from 0.5% to 5.0% by weight of a fatty acid ester of a member selected from the group consisting of glycerin, propylene glycol, mono- and dihydric alcohols of from one to twelve carbon atoms, inclusive, and polyethylene glycols having a molecular weight of between about 200 and about 6000, said fatty acid being selected from a group consisting of long chain saturated and un-saturated monocarboxylic acids having from twelve to twenty carbon atoms, inclusive.
2. A composition as defined in claim 1 in which the vegetable oil is peanut oil.
3. A composition as defined in claim 1 in which the fatty acid ester is glycerol monostearate.
4. A composition as defined in claim 1 in which the vegetable oil is peanut oil and the fatty acid ester is glycerol monostearate.
5. A composition as defined in claim 1 in which said gelled vehicle, in addition, contains about 0.02% to 0.15% by weight of a fatty acid salt of a member selected from the group consisting of sodium, potassium and lithium, said fatty acid being selected from a group consisting of long chain saturated and unsaturated monocarboxylic acids having from twelve to twenty carbon atoms, inclusive.
6. A composition as defined in claim 5 in which the vegetable oil is peanut oil.
7. A composition as defined in claim 5 in which the fatty a??? ester is glycerol monostearate.
8. A composition as defined in claim 5 in which the fatty acid salt is potassium stearate.
9. A composition as defined in claim 5 in which the vegetable oil is peanut oil, the fatty acid ester is glycerol monostearate and the fatty acid salt is potassium stearate.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US45603074A | 1974-03-29 | 1974-03-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1052697A true CA1052697A (en) | 1979-04-17 |
Family
ID=23811160
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA221,421A Expired CA1052697A (en) | 1974-03-29 | 1975-03-06 | Composition for treating mastitis in animals |
Country Status (8)
| Country | Link |
|---|---|
| BE (1) | BE827361A (en) |
| CA (1) | CA1052697A (en) |
| DE (1) | DE2512391C2 (en) |
| DK (1) | DK143438C (en) |
| FR (1) | FR2265408B1 (en) |
| GB (1) | GB1456349A (en) |
| NL (1) | NL7502808A (en) |
| ZA (1) | ZA751451B (en) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1547164A (en) * | 1975-08-14 | 1979-06-06 | Beecham Group Ltd | Veterinary compositions |
| IT1190445B (en) * | 1985-11-08 | 1988-02-16 | Fatro Spa | VETERINARY COMPOSITIONS BASED ON ANTIMICROBIAL AGENTS AND THEIR USE |
| SE457693B (en) * | 1986-07-01 | 1989-01-23 | Drilletten Ab | COMPOSITION WITH REGULATED RELEASE WAS A BIOLOGICAL MATERIAL LOST OR DISPERSED IN AN L2 PHASE |
| DK16290D0 (en) * | 1990-01-19 | 1990-01-19 | Spindel & Spinnfluegelfab Veb | PATTERN TREATMENT NAME NECESSARY TO FIGHT MASTITIS |
| GB2273443B (en) * | 1992-12-08 | 1997-01-08 | Bimeda Res Dev Ltd | Veterinary composition for the treatment of mastitis |
| AU1530697A (en) * | 1996-09-06 | 1998-03-26 | Minnesota Mining And Manufacturing Company | Antimicrobial compositions |
| ES2183223T5 (en) | 1996-12-18 | 2015-05-07 | Bimeda Research & Development Limited | Intra-mammary composition for veterinary use that does not contain anti-inflammatory agents |
| FR2833500A1 (en) * | 2001-12-17 | 2003-06-20 | Veyron Et Froment Lab | New anhydrous, oily gel for use in the manufacture of e.g. cosmetics, oral dental products or pharmaceuticals |
| NZ519112A (en) * | 2002-05-22 | 2004-12-24 | Interag | Drug delivery device for administration of active agent to mammary gland cavity |
| US7842791B2 (en) | 2002-12-19 | 2010-11-30 | Nancy Jean Britten | Dispersible pharmaceutical compositions |
| US20040197422A1 (en) * | 2002-12-20 | 2004-10-07 | Pfizer Inc | Veterinary compositions for treating mastitis |
| GB0229642D0 (en) * | 2002-12-20 | 2003-01-22 | Pfizer Ltd | Veterinary compositions for treating mastitis |
| CN1980614B (en) | 2004-02-02 | 2011-12-28 | 百美达研究与发展有限公司 | Device for treating animal papillary ducts |
| CA2944753A1 (en) | 2004-02-02 | 2005-08-11 | Bimeda Research & Development Limited | Sequential delivery injector device |
| JP5318770B2 (en) | 2006-10-10 | 2013-10-16 | ウィスコンシン アルムニ リサーチ ファンデイション | Intramammary nipple sealant formulation and method of using the same to reduce or eliminate visual defects in ripened cheese |
| UA106226C2 (en) * | 2009-04-08 | 2014-08-11 | Висконсин Алумни Рисерч Фаундейшн | Intra-mammary teat sealant formulation and method of using same to reduce or eliminate visual defects in aged cheeses |
-
1975
- 1975-03-06 CA CA221,421A patent/CA1052697A/en not_active Expired
- 1975-03-10 ZA ZA00751451A patent/ZA751451B/en unknown
- 1975-03-10 NL NL7502808A patent/NL7502808A/en not_active Application Discontinuation
- 1975-03-14 DK DK106175A patent/DK143438C/en not_active IP Right Cessation
- 1975-03-21 DE DE2512391A patent/DE2512391C2/en not_active Expired
- 1975-03-28 BE BE154927A patent/BE827361A/en not_active IP Right Cessation
- 1975-03-28 FR FR7509948A patent/FR2265408B1/fr not_active Expired
- 1975-04-01 GB GB1331075A patent/GB1456349A/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| BE827361A (en) | 1975-09-29 |
| DK106175A (en) | 1975-09-30 |
| NL7502808A (en) | 1975-10-01 |
| AU7909675A (en) | 1976-09-16 |
| DK143438B (en) | 1981-08-24 |
| DE2512391A1 (en) | 1975-10-02 |
| DK143438C (en) | 1981-12-21 |
| FR2265408A1 (en) | 1975-10-24 |
| DE2512391C2 (en) | 1986-10-09 |
| ZA751451B (en) | 1976-02-25 |
| GB1456349A (en) | 1976-11-24 |
| FR2265408B1 (en) | 1978-08-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1052697A (en) | Composition for treating mastitis in animals | |
| EP0022289B1 (en) | Antimicrobial polymer compositions and use thereof in medical devices | |
| US4479795A (en) | Antimicrobial polymer compositions | |
| JP2632842B2 (en) | Antimicrobial preservation composition | |
| Iba et al. | Studies on the use of a formic acid‐propionic acid mixture (Bio‐add™) to control experimental Salmonella infection in broiler chickens | |
| TWI504418B (en) | Pharmaceutical topical compositions comprising ozenoxacin and uses of the same | |
| CA2366793C (en) | Propofol formulation with enhanced microbial characteristics | |
| US20160193293A1 (en) | Ointment containing a hydrolyzed fibroin and manufacturing method of same | |
| CN107432834A (en) | Antiseptic-free composition with antibacterial effect and preparation method and application thereof | |
| DD255667A5 (en) | KOEDER FOR ANIMALS | |
| US4034099A (en) | Compositions and method for treating mastitis in milk animals | |
| CA2264286A1 (en) | Antimicrobial compositions | |
| KR20110101138A (en) | Preservative system for emulsion-based therapeutic topical formulations | |
| CN112654369A (en) | Biocompatible material | |
| EP0180743A1 (en) | Liquid preparation containing living microorganisms, process for preparing it, pelleted product containing living microorganisms and process for preparing it | |
| KR102482158B1 (en) | gel composition for disinfection and manufacturing method thereof | |
| CN110248702A (en) | The composition useful for the cosmetic treatments of Oily | |
| US4067967A (en) | Composition for topical application to humans and animals | |
| ES2824477T3 (en) | Emollient composition | |
| CH641351A5 (en) | RECTALLY ADMINISTRABLE PHARMACEUTICAL PRODUCT. | |
| ZA200300611B (en) | Pharmaceutical composition having specific water activity. | |
| CN111249168A (en) | Composition for preventing mosquito bites and preparation method thereof | |
| RU2605631C1 (en) | Agent for prevention of mastitis in cattle | |
| JP4398187B2 (en) | Moisturizing gloves and manufacturing method thereof | |
| US2793976A (en) | Method for controlling hemorrhage in dehorned cattle |